3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
6
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Acute
2
Glioblastoma
2
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Renal Insufficiency
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pathologic Complete Response
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Melanoma
1
Lung Neoplasms
1
Liver Failure
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioma
1
Interventions
pembrolizumab
6
Cetuximab
5
olaparib
3
atezolizumab
3
Injections
3
fludarabine
2
Trastuzumab
2
Docetaxel
2
Cyclophosphamide
2
Bevacizumab
2
zimberelimab
1
zansecimab
1
tocilizumab
1
taxane
1
spartalizumab
1
somatostatin receptor 2
1
ribociclib
1
pralsetinib
1
pertuzumab
1
pegylated granulocyte colony-stimulating factor
1
lenvatinib
1
ipatasertib
1
inavolisib
1
fludarabine phosphate
1
entrectinib
1
encorafenib
1
durvalumab
1
dapagliflozin
1
cemiplimab
1
brigimadlin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Solid Tumors
×
veliparib
×
1 year
×
Clear all
No trials found.